2015 ACVIM Forum Research Abstract Program

Thirty one privately owned dogs with suspected chronic pancreatitis were enrolled into the study. Dogs were included based on two consecutive canine pancreatic lipase immunoreactivity (cPLI) measurements >400 lg/L within 12 AE 4 days and a serum triglyceride concentration below 500 mg/dL. Dogs with major concurrent disease (e.g., renal disease, icterus) were excluded. Dogs were either treated with 12 mg/kg/d (n = 12) or 24 mg/kg/ d (n = 19) oral CM for 26 AE 5 days. A complete blood count, serum biochemistry profile, and assays for the measurement of cPLI, canine trypsin-like immunoreactivity (cTLI), cobalamin, and folate concentrations were performed before and after treatment. In addition, serum TGF-b1, S100A12, and C-reactive protein (CrP) concentrations were evaluated after completion of the trial as a batch measurement. Pre-and post-treatment results were compared using a paired t-test for normally distributed data sets and a Wilcoxon matched-pairs test when Gaussian distribution could not be assumed. The significance threshold was set at P = 0.05 Serum cPLI concentrations significantly decreased from pretreatment (median 690 lg/L; range 344 to 6,052 lg/L) to posttreatment (median 514 lg/L; range 125 to 2,836 lg/L; P = 0.0409) in both treatment groups combined and in the subgroup of dogs treated with 24 mg/kg/d oral CM from pre-treatment (median: 847 lg/L; range: 414 to 2,024 lg/L) to posttreatment (median: 520; range: 193 to 2,580 lg/L; P = 0.016). In dogs treated with 12 mg/kg/d oral CM, serum cPLI concentration did not change significantly between pre-treatment (median 501 lg/L; range 344 to 6,052 lg/L) and post-treatment (median 453 lg/L; range 125 to 2,836 lg/L; P = 0.9697) measurements. Serum cobalamin concentrations decreased significantly between pre-treatment (mean: 843 ng/L; SD: AE 198 ng/L) and post-treatment (mean: 681 ng/L; SD: AE 239 ng/L; P = 0.003) in both treatment groups combined, as well as both subgroups (12 mg/kg/d oral CM; pre-treatment: mean 868 ng/L; SD: AE 108 ng/L; posttreatment: mean 695 ng/L; SD: AE 223 ng/L P = 0.0363 and 24 mg/kg/d oral CM; pre-treatment: mean 749 ng/L; SD: AE 229 ng/L; post-treatment: mean 641 ng/L; SD: AE 252 ng/L: P = 0.045). Treatment resulted in no significant differences in serum concentrations of cTLI, folate, TGF-b1, S100A12, or CrP in all dogs combined or either subgroup.